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Fig. 2. Suction pressure (SP) over pulsatile ventricular 
pressure (PVP) at different assisted pump flows. The slope 
of the lines is a measure of the momentary pressure drop 
at a certain magnitude of pulsatility of the ventricular 
pressure. Arrows indicate the example in the text. (From 
De Paulis R, Englehardt H, Chiariello L, Reul H, Morea 
M. In vitro evaluation of left ventricular assistance by 
cannulation of both femoral arteries. Int J Artif Organs 
1990;13:237-46. Published with permission of Wichting 
Editore, Milan, Italy.) 
ascribed to inertia and increased friction because of fluid 
acceleration i side the cannula. In our model, at 3 L/min 
of bypass flow and a prosthetic ventricular pressure vary- 
ing from 5 to 50 mm Hg, the suction pressure ranged from 
-92 to -56 because the pressure drop changed from 97 to 
106 mm Hg (Fig. 2). 2 This means that for the same 
intraventricular pressure the pressure drop is smaller 
where the magnitude of the pulsatility is less (as in the 
case of a failing ventricle) and that any increase of the 
intraventricular pressure (as in the case of ventricular 
recovery) will result in a lower suction pressure. From this 
example, data for a 5 mm inner diameter cannula could be 
extrapolated. 
On the basis of our data, we think that  5 mm inner 
diameter cannula might betoo small to achieve asufficient 
bypass flow in an adult. On the other end, we are well 
aware that a bigger cannula will make more difficult the 
prevention of lower limb ischemia, which is critical in this 
type of ventricular assistance in which both femoral 
arteries are cannulated. On the other hand, Babic and 
coworkers 3 have clinically used a percutaneous left heart 
bypass either as a left atrial-aortic bypass or as a left 
ventricle-aortic bypass with a long 14F cannula with a 
Teflon sheath and a minimally nonocclusive roller pump. 
They were able to achieve flows ranging from 1.5 to 3.5 
L/min, kinking of the cannula was never noticed, and 
hemolysis and other hematologic alterations were never 
clinically relevant. Furthermore, they claimed that leg 
ischemia could be simply prevented by positioning the 
arterial inflow sheath tip into the aorta and not into the 
iliac artery. 
Although percutaneously applied LV bypass combines 
several advantages over other LV assistance systems, it 
has never gained widespread clinical use. The reason lies 
within the difficult compromise in the choice of a cannula 
with a size sufficient in providing an adequate flow but 
small enough to avoid an impaired perfusion of the lower 
limbs. Although it might be effective for LV assistance 
during short-term procedures uch as coronary angio- 
plasty, it is likely to be inadequate for intermediate-term 
or long-term ventricular support. 
In conclusion Ide and coworkers are to be congratu- 
lated for the brilliant idea of integrating pulsatility in a
system of LV assistance with the intention of balancing for 
incomplete LV unloading. However, on the basis of our 
experience, we still doubt he possibility of obtaining ood 
drainage through a 15F inner diameter long cannula, and 
at the same time we believe that a 20F outer diameter 
cannula is likely to cause limb ischemia when left in place 
for more than a few hours. 
Ruggero De Paulis, MD 
Harald Engelhardt, BE 
L. Chiariello, MD 
Cardiac Surgery Department 
Universitil di Roma Tor Vergata 
Rome, Italy 
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Reply to the Editor: 
We acknowledge Dr. De Paulis and his colleagues for 
their suggestion about the clinical application of the 
integrated cardioassist catheter (ICAC) method, a pulsa- 
tile left ventricular-aortic bypass method eveloped by us. 
Regarding clinical use, we have developed the ICAC as a 
left ventricular bypass system that can be easily applied in 
cases of left ventricular failure. It is used for conditions in 
which the intraaortic balloon pump is insufficient but the 
use of a conventional left ventricular assist device would 
be excessive. In developing this system, we intended to 
obtain a partial left ventricular bypass to provide short- 
term (about 1 week) support. As pointed out by Dr. De 
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Fig. 1. The ICAC device. 
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Fig. 2. Pressure-flow relationship. (From Yamaguchi A, Ide H, Kawahito K, et al. A New Method for 
Insertion and Use of the Integrated Cardioassist Catheter [ICAC] Left Ventricular Assist Device. Jpn J 
Artif Organs 1992;21:353-6; published with permission.) 
Paulis and colleagues, the dilemma is to obtain higher 
blood flow, a function essential for left ventricular bypass, 
and to reduce the outer diameter of the catheter for the 
prevention of the lower leg myonephropathic-metabolic 
syndrome, on the assumption that the insertion site is the 
femoral artery. The maximal flow rate was chosen on the 
basis of our experiences with percutaneous cardiopulmo- 
nary bypass in 30 consecutive patients and several cases of 
cardiac failure. Because most of the patients required the 
flow support at about 2 L/min, we set the maximum flow 
rate of the ICAC for clinical use at 2 L/rain and prepared 
the catheter. Fig. 1 is a schematic illustration of ICAC for 
clinical use. The ICAC is made of polyurethane and is 
coated with heparin so as to decrease systemic heparin. Its 
inner shape is not oval. The actual inner diameter is about 
15F, and the outer diameter is about 20F. As an in vivo 
study, a mock circulation study was conducted with hep- 
arinized human blood. The results obtained with our 90 
cm catheter were similar to those obtained by Dr. De 
Paulis' group. We obtained the maximal flow rate of about 
2 L/min with a pressure drop of 100 mm Hg and about 2.5 
L/min at 150 mm Hg I (Fig. 2). At no time did the catheter 
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collapse. In fact, in the in vitro study in dogs in which 
ICAC for human use was applied, 2we confirmed that a 
flow rate of 2 L/rain was obtained at an intracirculatory 
negative pressure of 100 to 140 mm Hg at the proximal 
portion of the centrifugal pump. 
The main point of our article~is to show by experiments 
in dogs that despite incomplete decompression ( ot the 
total decompression of the left ventricle reported previ- 
ously by others 4) and also by left ventricular drainage, the 
peripheral circulation can be maintained and the left 
ventricle supported by adding electrocardiographically 
gated pulsatility. Thus pulsatility compensates for the 
limited maximal flow rate, which is the essential problem 
associated with our catheter. If the experimental results 3
are applied strictly and quantitively to the clinical situa- 
tion, we have to admit the necessity of an ICAC maximal 
flow rate of 3 L/min, taking into consideration the safety 
margin pointed out by Dr. De Paulis. However, we have 
used the ICAC catheter for left ventricular bypass in two 
patients with profound left ventricular failure causedby 
ischemic heart disease (reference No. 5 and unpublished 
data), and the maximum flow rate of 2 L/min was obtained 
in both cases, similar to in vivo and in vitro experiments. 
With this flow rate, peripheral circulation could be main- 
tained; moreover, echocardiographic f ndings revealed 
improvement in the left ventricular performance of the 
ischemic heart itself, and changes in serum free hemoglo- 
bin levels were within the acceptable range. 
Because we have applied our catheter in only two cases 
so far, we cannot yet draw a definite conclusion as to 
whether the maximal flow rate of our ICAC for clinical 
use is acceptable. We want to investigate further the 
efficacy of the left ventricular bypass method by ICAC in 
a number of cases. 
Hirofumi Ide, MD a 
Atsushi Yamaguchi, MD b 
Department of Thoracic and Cardiovascular Surgery 
Kyorin Medical School 
Tokyo, Japan ~ 
Department of Cardiovascular Surgery 
Jichi Omiya Medical Center 
Saitama, Japan b 
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Evaluating the impact of magnetic resonance 
imaging on patients with operable non-small-cell 
lung cancer and unilateral adrenal masses: 
Importance of appropriate technique 
To the Editor: 
I appreciate the recent effort by Burt and associates a to 
address the ability of magnetic resonance imaging (MRI) 
to distinguish between benign and malignant adrenal 
masses in patients with non-small-cell lung cancer. Unfor- 
tunately, their methods preclude adequate valuation. 
Butt and associates do not describe their MRI tech- 
nique adequately. A simple label of "T2-weighted" is not 
sufficient. A wide variety of parameters, uch as repetition 
time (TR) and echo time (TE), can affect image contrast 
on "T2-weighted" images. The limitations of this study, 
however, extend beyond this omission. 
In their introduction, the authors efer to early studies 
using midfield (0.35 to 0.5 T) MRI instruments in which 
adrenal adenomas were found to have signal intensity 
similar to that of liver. The authors then refer to two more 
recent studies using higher field strength instruments (1.5 
T) which "tried to develop MRI criteria to predict 
whether an adrenal mass is benign or malignant. ''2' 3 In 
particular, these authors found that at 1.5 T, the liver is 
not a suitable standard for visual comparison to adrenal 
glands and that T2 ratios were far more useful. Unfortu- 
nately, Burt and colleagues have attempted to discrimi- 
nate between benign and malignant adrenal masses at 1.5 
T using the already discredited technique of visual com- 
parison to liver. 
Simple comparison of signal intensities on T2-weighted 
images cannot distinguish accurately between adrenal 
adenomas and metastases because lipid (abundant in 
adrenal adenomas) and neoplastic tissue both have high 
signal intensity on most T2-weighted images. A more 
direct method for distinguishing between benign and 
malignant adrenal masses, based on specific histologic 
differences between these entities, was suggested by Le- 
roy-Willig and coworkers 4 in 1987. In this in vitro pilot 
study, these authors successfully used chemical-shift 
(spectroscopic) magnetic resonance techniques for reli- 
able identification of small quantities of lipid within 
benign adrenal masses. In a subsequent study in 1989, 
they 5confirmed these principles in vivo using techniques 
not available at most MRI centers. Subsequently in 1992, 
my colleagues and 16 published our results with chemical- 
shift MRI techniques that were commercially available on 
many MRI systems, including the system as used by Burt 
and associates. This chemical-shift MRI technique has 
subsequently been confirmed by other authors as highly 
accurate for distinguishing benign from malignant adrenal 
masses. 7 Thus we currently recommend chemical-shift 
MRI as a reliable and practical method for distinguishing 
